EBC-46 is beyond the very early stages of development, with highlights including:
Positive Animal Trials: Veterinary Clinical Phase III studies treating over 100 spontaneous tumours in dogs, cats and horses resulted in total disintegration of the tumour with rapid healing in less than two weeks.
No Adverse Side Effects: The drug was well tolerated in all cases with no adverse side effects.
Commercialisation For The Vet Market Imminent: In final preparation for registration of the drug for the Veterinarian market in Australia and New Zealand.
Human Clinical Trials Imminent: Clinical Phase I studies in humans are due to commence early 2011.
Secure Intellectual Property: Strong IP protection with a world-wide patent pending for both composition of matter and use.
Drug Production In Progress: Large scale production of the drug is already in progress with projected supply cost to be well within sound commercial parameters.